The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes
Open accessAbstract
Aims To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality.Methods We identified a clinical cohort of male veterans in the United States who were ≥65years old with T2D and free from ARCs during 2002-2003. ARC diagnoses during 2004-2012 were analyzed using latent class modeling adjusted for confounders.Results The cohort consisted of 41,204 T2D men with age 74.6±5.8years, HbA1c 6.5±0.97%, and 8393 (20.4%) metformin users. Four ARC classes were identified. 'Healthy Class' (53.6%): metformin reduced likelihoods of all ARCs (from 0.14% in dementia to 6.1% in CVD). 'High Cancer Risk Class' (11.6%): metformin reduced likelihoods of CVD (13.3%), cancer (45.5%), depression (5.0%), and FRD (13.7%). 'High CVD Risk Class' (17.4%): metformin reduced likelihoods of CVD (48.6%), cancer (3.2%), depression (2.8%), and FRD (6.3%). 'High Frailty Risk Class' (17.2%): metformin reduced likelihoods of CVD (18.8%), cancer (3.9%), dementia (3.8%), depression (15.6%), and FRD (23.8%).Conclusions Metformin slowed ARC development in old men with T2D, and these effects varied by ARC phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In our case, the factors after 5 years of treatment are 0.52 for dementia, 0.33 for cardiovascular diseases, 0.32 for cancer, 0.29 for depression and 0.58 for frailty-related diseases.”
From The economic value of targeting aging (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on ref. 28, metformin has a sizable effect on LE. For the case in which treatment starts at age 75, LE at birth rises by 2.9 years, at 20 years rises by 3.0 years, at 40 years rises by 3.0 years, at 60 years rises by 3.3 years, and at 80 years rises by 4.3 years. The additions to remaining HLE vary from 1.7 to 2.5 years.”
From The economic value of targeting aging (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As ref. 28 only includes men over the age of 65 with diabetes, the factors may not accurately capture the impact of metformin on women, individuals who do not have diabetes, or those aged under 65.”
From The economic value of targeting aging (2021) · cites this paper as [28]
In the citing paper
“treatment with metformin reduced the risk of multiple age-related diseases, including CVDs, cancer, depression, and frailty-related diseases”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [254]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 1×
“…and mortality prevention requires further investigation (for example, empagliflozin has shown potential CVD prevention benefit in adults with T2D (Zinman et al., 2015)), this study provides important data for designing prospective studies aimed at examining the pleiotropic effects of metformin…”
BackgroundPrediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly
Wolff, J. L., Starfield, B. H., & Anderson, G. F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.20.2269 · Cited by 2,237
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Cited by
Sorted by citations
Items 101–133 of 133
Considerations Regarding Public Use of Longevity Interventions
Liu, Y. J., McIntyre, R. L., & Janssens, G. E. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.903049 · Cited by 3
Practical Considerations in the Management of Frail Older People with Diabetes
Abdelhafiz, D., & Abdelhafiz, A. H. (2025) · Diseases · doi:10.3390/diseases13080249 · Cited by 7
Cognitive Impairment in Obesity and Diabetes
Carvalho, C., & Moreira, P. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_29 · Cited by 3
do Nascimento, N. B., Farias, H. R., Schons, T., Padilha, A. P. Z., da Costa, M. S., Peres, A. M., Santos¹, L. F. D. S., Dantas, R. M., Ramos, J. M. O., Rodrigues, M. S., et al. (2026) · Neurochemical Research · doi:10.1007/s11064-025-04658-7 · Cited by 2
Campbell, J. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823679-6.00013-8 · Cited by 2
Yeboah, K., Gyamfi, T., & Agyekum, J. A. (2024) · Alexandria Journal of Medicine · doi:10.1080/20905068.2024.2314796 · Cited by 3
Hafizova, A. Z., Семина, И. И., Олегович, Н. Д., & Moustafine, R. I. (2025) · Kazan medical journal · doi:10.17816/kmj382686 · Cited by 2
Metformin reduces the risk of frailty: evidence from a Mendelian randomization study
Chen, T., Liu, Y.-L., Qiu, H.-N., Lin, C.-Y., Wu, F., Li, J., & Lin, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01825-2 · Cited by 2
Novel update of interventional strategies of vascular aging in humans
Qiu, Y., Liu, Y., Liu, X., & Tao, J. (2020) · Aging Medicine · doi:10.1002/agm2.12124 · Cited by 1
Seki, T., Yamanashi, T., Shimura, A., Chang, G., Santiago, T. A., Phuong, N. J., Nguyen, H. D., Gorantla, N., Nishiguchi, T., Yamanishi, K., et al. (2025) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2025.07.003 · Cited by 1
Li, H., Li, X., & Liu, F. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113059 · Cited by 1
Cell senescence is a cause of frailty
Wan, T., Miwa, S., & von Zglinicki, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00013-4 · Cited by 1
Topçu, H., Yıldız, B. K., Yıldırım, Y., & Ağca, A. (2021) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20220087 · Cited by 1
Pan, Y., & Ma, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00004-5 · Cited by 1
Agyekum, J. A., & Yeboah, K. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2273-6527 · Cited by 1
Association of history of metformin use with delirium and mortality: A retrospective cohort studyPreprint
Yamanashi, T., Anderson, Z. M., Modukuri, M., Chang, G., Tran, T., Marra, P. S., Wahba, N. E., Crutchley, K. J., Sullivan, E. J., Jellison, S. S., et al. (2022) · medRxiv · doi:10.1101/2022.04.03.22273209 · Cited by 1
Kazi, N., & Abdelhafiz, A. H. (2025) · doi:10.1002/9781394205066.ch4 · Cited by 1
Mitchell, A., Price, M., & Cipriano, G. C. (2021) · medRxiv · doi:10.1101/2021.06.04.21258310
Total quality management (tqm) and systems thinking in translational science
Smith, R. E. F. (2018) · Journal of Translational Science · doi:10.15761/jts.1000244
Słomińska, D., Manikowska, K., Hoszman, M., Mikołajczak, P. Ł., & Winiarska, H. (2021) · Pharmacotherapy in Psychiatry and Neurology · doi:10.33450/fpn.2021.02.003
Nürnberger, J. I. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735417540.793562993
Campbell, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62141-4 · Cited by 3
Effects of hypoglycaemic therapy on frailty: a multi-dimensional perspective
Abdelhafiz, A. H. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168644
The Mechanism of Inflamm-Aging in Elderly Frailty Syndrome
叶赛·艾尼瓦尔, 米. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143869
Frailty in Older People with Diabetes Mellitus
Sinclair, A. J., & Abdelhafiz, A. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-57361-3_42
Espinoza, S. E., Broder, J. C., Wolfe, R. S., Ernst, M. E., Shah, R. C., Orchard, S. G., Woods, R. L., Ryan, J. L., & Murray, A. M. (2025) · GeroScience · doi:10.1007/s11357-025-01598-6 · Cited by 1
Self-citationZhao, N., Gao, Y.-F., Bao, L., Lei, J., An, H.-X., Pu, F., Cheng, R.-P., Chen, J., Ni, H., Sui, B.-D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14978245
Liu, P., Pan, Y., Song, Y., Zhou, Y., Zhang, W., Li, X., Li, J., Li, Y., & Ma, L. (2024) · Figshare · doi:10.6084/m9.figshare.26565935
The Potential Role of Antidiabetic Agents in Bipolar Disorder
Landivar, E., Gabriel, F. C., Daolio, L. D., & Lafer, B. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00375-2
Wilson, D. V., Acharjee, A., Duggal, N. A., Hombrebueno, J. R., Jones, S. W., Lewis, J. W., de Magalhães, J. P., Martínez-Serrato, Y., Mazaheri, A., McGettrick, H. M., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0346347
Chan, A. H. Y., Beyene, K. A., Lai, B., Kim, S., Wu, I., Al-Jawadi, R., Wu, M., Foot, H., Cheung, G., Walker, X. J., et al. (2026) · Rejuvenation Research · doi:10.1177/15491684261462413
A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose IntolerancePreprint
Musi, N., Wang, C.-P., MacCarthy, D., Feng, Z., Holmes, J. T., Masayoshi, S., Pirtskhalava, T., Aslamy, A., Wanagat, J., Brooke, R., et al. (2026) · medRxiv · doi:10.64898/2026.07.27.26359055
Self-citationMetformin treatment and effects on psychiatric behaviors: Measures of depression
Kumari, R., Dixit, T., Verma, S., Sawardekar, M., & Ravindran, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00017-8
Metadata
- Authors
- Wang, C.-P., Lorenzo, C., Habib, S. L., Jo, B., & Espinoza, S. E.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Stanford Medicine (US)
- Corresponding author
- Wang, Chen-Pin
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 31
- Issue
- 4
- Pages
- 679-686
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- PMC
- PMC5654524
- OpenAlex
- W2582066920
- Cited by
- 134
- References
- 50
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 10 · 2023: 16 · 2022: 23 · 2021: 16 · 2020: 18 · 2019: 14 · 2018: 12 · 2017: 3
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Diabetes and its Complications (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R21CA161180)
- National Institute on Aging (P30AG04427)
- National Institute on Drug Abuse (R01DA31698)
- South Texas Veterans Health Care System, San Antonio, Texas
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Keywords
- metformin, type 2 diabetes, older men, age-related comorbidities, cardiovascular disease, cancer, depression, dementia, frailty, mortality, veterans, treatment effect heterogeneity, latent class analysis
- MeSH terms
- Aged, Aged, 80 and over, Aging, Cardiovascular Diseases, Dementia, Depression, Diabetes Mellitus, Type 2, Drug Resistance, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Metformin, Mortality, Neoplasms, Risk, United States, United States Department of Veterans Affairs, Cohort Studies, Comorbidity, Prevalence, Frail Elderly, Electronic Health Records, Veterans Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
